Novel JAK2 Inhibitor Piperadine Aniline Derivatives of Ruxolitinib to Treat Myelofibrosis

FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE

Contact

Haskell Adler PhD MBA CLP
Senior Licensing Manager
Haskell.Adler@Moffitt.org
(813) 745-6596

21MA004N